Headquartered in Austin, TX Fiscal year ends December NASDAQ: SAVA cassavasciences.com
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company focused on developing novel therapies that modulate the filamin A protein for the treatment of central nervous system disorders. The company's lead investigational candidate is simufilam, which is being developed for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, a rare genetic disorder affecting approximately 45,000 people in the U.S. where over 60% of patients remain refractory to existing antiepileptic therapies. The company previously pursued an Alzheimer's disease program which has been fully phased out. Filana is currently a pre-revenue company with its lead program under an FDA clinical hold, and it trades on the NASDAQ exchange. Updated
Meme stocks traded well-mixed at midday Thursday. The morning's most surprising turn came from a stock that missed estimates and gave lower guidance but still traded higher.
Meme stock winners far outnumbered losers on Tuesday, and one of those winners is posting another big gain in Wednesday's premarket.
On Tuesday, the biggest winner among meme stocks was Cassava Sciences, while Camber Energy took the biggest hit.
Retail investors may be revving up a short squeeze on a stock that was hammered on Monday.
U.S. retail investors now own 12 times more stock than do hedge funds, and Americans have a greater percentage of their money in savings and stock portfolios than at any time since…
An FDA directive has hammered a coronavirus vaccine maker Friday morning as a new variant of the infection is discovered in South Africa.
Here's a look at why five favorite retail stocks were all trading up by double digits at noontime Friday.
A federal investigation into one company's research data has caused its stock to crater, while a rebuttal of a short seller's claims have lifted another.
EV stocks were losing some of their recent gains, and one biotech has announced a new federal investigation.
A company developing a treatment for Alzheimer's disease got a big boost Thursday when a journal in which the company published a report said it found no basis for allegations of data…
Filana Therapeutics, Inc. (NASDAQ: FLNA) is a clinical-stage biotechnology company focused on developing novel therapies that modulate the filamin A protein for the treatment of central nervous system disorders.
The Wall Street consensus 12-month price target for SAVA is $8.00.
